CCL17 and rheumatoid arthritis: Significantly, we report here that GC treatment can suppress GM-CSF-induced CCL17 production in peripheral blood mononuclear cells (PBMCs) from RA patients as well as in synovial cells from an inflammatory arthritis mouse model.